Skip Navigation LinksHome > April 2015 - Volume 19 - Issue 2 > Milnacipran in Provoked Vestibulodynia: Efficacy and Predic...
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0000000000000057
Original Articles: Vulva and Vagina

Milnacipran in Provoked Vestibulodynia: Efficacy and Predictors of Treatment Success

Brown, Candace PharmD1; Bachmann, Gloria MD2; Foster, David MD3; Rawlinson, Leslie1; Wan, Jim PhD4; Ling, Frank MD5,6

Collapse Box


Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success.

Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype.

Results: Milnacipran (50–200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p ≤ .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04–10.50, p = .043).

Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.

Copyright © 2015 by the American Society for Colposcopy and Cervical Pathology


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.